Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.

    Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 1

    As noted in a recent article published in Inside Precision Medicine, in 1992 gene therapy was often discussed but seldom practiced.  When Jim Wilson MD, PhD attended Penn State, gene…

    Continue Reading Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 1

    The FDA has Issued a Complete Response Letter to Xspray Pharma Delaying Approvals Affecting ALL and CML

    Xspray Pharma, the developer of the drug dasatinib, was recently issued a Complete Response Letter (CRL) by the FDA while waiting for corrective actions, according to Cancer Network.  Based on…

    Continue Reading The FDA has Issued a Complete Response Letter to Xspray Pharma Delaying Approvals Affecting ALL and CML

    Syndax Pharmaceutical’s Revumenib Meets its Primary Endpoint to Treat Relaxed/Refractory Acute AML

    According to a press release from Syndax Pharmaceuticals, the developer of Revumenib, the drug met its primary endpoint resulting in complete remission (CR) or CR with partial recovery.  Relapsed or…

    Continue Reading Syndax Pharmaceutical’s Revumenib Meets its Primary Endpoint to Treat Relaxed/Refractory Acute AML

    The FDA Now Requires Increased MRI Monitoring for Alzheimer’s Patients Who Are Treated with Leqembi

    After the death of six patients, the FDA has announced that it will require earlier and more frequent monitoring of the monoclonal antibody Leqembi, the brand name for the Alzheimer’s…

    Continue Reading The FDA Now Requires Increased MRI Monitoring for Alzheimer’s Patients Who Are Treated with Leqembi

    Denmark Researchers Have Created a Light-Based Technology That Improves Cognitive Function for Alzheimer’s Patients

    Researchers at UC Berkeley, DTU, and OptoCeutics in Denmark have created a non-medical light-based technology that improved cognitive function for Alzheimer’s patients who have participated in previous clinical trials. The…

    Continue Reading Denmark Researchers Have Created a Light-Based Technology That Improves Cognitive Function for Alzheimer’s Patients

    Updating the findings from Phase 3 DREAMM 7 trials for Relapsed/refractory Multiple Myeloma Patients

    Lancet Oncology Recently published reports updating the findings from the phase 3 DREAMM 7 trial involving 494 patients averaging ages 64.5 years with the median follow-up of 39.4 months. Accordingly, patients…

    Continue Reading Updating the findings from Phase 3 DREAMM 7 trials for Relapsed/refractory Multiple Myeloma Patients

    And the Good News is . . .Cancer Survivors in the United States are Projected to Exceed 22 million people by 2035

    Here's a more detailed explanation. The newest American Cancer Society study just released suggests that a diagnosis of cancer is no longer a death sentence. According to a recent U.S.…

    Continue Reading And the Good News is . . .Cancer Survivors in the United States are Projected to Exceed 22 million people by 2035

    New Study: Extending Imaging Including the Heart Upon Arrival in E.R. Helps Determine Cause of a Stroke

    The study, published in the journal The Lancet Neurology and reported by MedicalXpress.com, is the first to demonstrate the urgency of extending imaging that includes the heart. This must be accomplished within…

    Continue Reading New Study: Extending Imaging Including the Heart Upon Arrival in E.R. Helps Determine Cause of a Stroke